Business Wire

Citi Selected as Financial Advisor to Gavi, The Vaccine Alliance’s COVAX Facility

2.11.2020 16:00:00 EET | Business Wire | Press release

Share

Citi today announced the firm has been selected by Gavi, the Vaccine Alliance, to be the financial advisor for the COVAX Facility, its global procurement mechanism for COVID-19 vaccines.

The COVAX Facility is part of COVAX, a global, multilateral initiative aimed at developing, manufacturing and deploying COVID-19 vaccines on a fair and equitable basis. It is co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO) – working in partnership with developed and developing country vaccine manufacturers, UNICEF, the World Bank, Civil Society Organizations and others.

Citi will provide Gavi with expert advice on structures to mitigate sovereign, credit and operational risk as the COVAX Facility seeks to facilitate pooled procurement and equitable distribution of safe and effective COVID-19 vaccines from multiple pharmaceutical manufacturers to all COVAX participating economies once they reach licensure.

“Citi considers this assignment to be a clear demonstration of who we are as a firm and it builds on the work we’re doing to help combat this crisis on many fronts,” said Jane Fraser, President of Citigroup and CEO of Global Consumer Banking. “Funding of vaccines is at the core of bringing this crisis to an end, and Citi is honored to contribute to this unprecedented effort. We are bringing top talent together from around the firm to support Gavi in achieving its global objectives.”

In its first phase, and up until the end of 2021, the COVAX Facility aims to secure and deliver 2 billion doses of vaccines to be distributed to member countries’ populations. The facility currently counts over 180 sovereign government entities as participants.

In its role as advisor, Citi will advise and assist in finding risk mitigation and execution strategies in connection with the facility, including supporting the building of strategies to operationalize and maintain the COVAX Facility.

“COVAX represents the best chance to provide people in all countries with rapid, fair and equitable access to COVID-19 vaccines as soon as they become available. We’re delighted to engage Citi, allowing the COVAX Facility to benefit from expert external advice to complement our in-house expertise, supporting our essential work mitigating risk and structuring the COVAX Facility to be as effective as possible,” said Dr. Seth Berkley, Chief Executive Officer, Gavi.

Throughout the pandemic, Citi has worked closely with governments and the private sector to find liquidity alternatives and funding solutions in response to COVID-19. This has included large targeted development bank and NGO efforts for the pandemic, including COVID-19 emergency programs by the World Bank, Africa Development Bank, the New Development Bank, and Gavi’s own International Finance Facility for Immunisation (IFFIm), where Citi recently acted as joint bookrunner on its $500m vaccine bond.

“Just, rapid and efficient funding and distribution of COVID-19 vaccines remains our best hope of ending this crisis, and we are committed to optimizing the COVAX Facility for that purpose, said Jay Collins, Vice Chairman, Banking, Capital Markets and Advisory at Citi and the lead advisor for the Citi team. “The size and complexity of this facility is unprecedented, and its urgency for the world is paramount,” he continued.

“We are pleased to partner with Citi on this landmark endeavor,” said Assietou Sylla Diouf, Managing Director of Finance & Operations, Gavi. “Never has such a facility been more critical given the crisis we are currently facing. Citi’s presence in over 160 countries and jurisdictions and its expertise will help to ensure the financial mechanics of the COVAX Facility are best able to support COVAX’s ambitious goals of ending the acute phase of the pandemic by the end of 2021.”

Citi remains committed to supporting clients and community partners to help drive a positive socially and environmentally sustainable response to COVID-19. Citi and the Citi Foundation have committed more than $100 million to date in support of COVID-19-related community relief efforts globally. Citi is proud of its efforts to fund stakeholders across multiple United Nations Sustainable Development Goals (SDGs), and is particularly proud of the contribution this work with Gavi will make to SDG 3: Ensure healthy lives and promote well-being for all at all ages.

Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Sophia Anthony
Citi Global Public Affairs
Banking, Capital Markets & Advisory Communications
+1 (212) 816-7140
sophia.anthony@citi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TVCMALL MWC 2026 -tapahtumassa: johtava mobiilitarvikkeiden tukkukauppa ja älykäs hankinta1.3.2026 08:00:00 EET | Tiedote

MWC Barcelona 2026 korostaa tekoälyn, yhteyksien ja älykkäämpien teknologisten järjestelmien kasvavaa merkitystä, ja samalla mobiilitarvikemarkkinat siirtyvät uuteen vaiheeseen, jota leimaavat nopeus ja monimutkaisuus. Tuotekategoriat laajenevat jatkuvasti, muotoilut ja tyylit päivittyvät yhä nopeammin, ja jälleenmyyjiltä odotetaan reagointia markkinamuutoksiin entistä lyhyemmissä sykleissä. Tuotevalikoiman ajantasaisena pitäminen samalla kun hankintaa hallitaan tehokkaasti on muodostunut todelliseksi haasteeksi jälleenmyyjille ja jakelijoille eri puolilla Eurooppaa. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20260121785166/fi/ TVCMALL MWC 2026 -tapahtumassa: johtava mobiilitarvikkeiden tukkukauppa ja älykäs hankinta MWC Barcelona 2026 - Tapahtumassa TVCMALL korostaa rooliaan Euroopan johtavana yhden luukun puhelin tarvikkeita tukkutoimittajana, keskittyen selkeästi siihen, että tukkukauppa ja hankinta olisivat helpompi

TVCMALL at MWC 2026: Leading Mobile Accessories Wholesale and Smarter Sourcing1.3.2026 08:00:00 EET | Press release

As MWC Barcelona 2026 highlights the growing role of AI, connectivity, and smarter technology systems, the mobile accessories market is entering a new phase defined by speed and complexity. Product categories continue to expand, designs and styles update faster, and retailers are expected to respond to market changes in shorter cycles. Keeping product lines up to date while managing sourcing efficiently has become a real challenge for retailers and distributors across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121405485/en/ TVCMALL at MWC 2026: Leading Mobile Accessories Wholesale and Smarter Sourcing At MWC Barcelona 2026, TVCMALL highlights its role as a leading one-stop mobile accessories wholesaler in Europe, with a clear focus on making wholesale and sourcing easier, faster, and more reliable. With more than 18 years of experience, TVCMALL works closely with 30+ leading retail partners across Europe, supp

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 02:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen. According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances. IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and lice

IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p

HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release

HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye